Please upgrade your browser.
Renal cell carcinoma (RCC) incidence rates are higher in developed countries, where up to half of the cases are discovered incidentally. Declining mortality trends have been reported in highly developed countries since the 1990s.
This study will explore the effectiveness of the experimental drug known as CRLX101 combined with bevacizumab (Avastin), in patients with metastatic renal cell carcinoma (RCC).
How does exercise benefit cancer patients? It turns out that there are a number of different reasons why exercise has such a positive impact on cancer patients. The immune system becomes more activated during exercise...
A higher intake by postmenopausal women of the natural antioxidant lycopene, found in foods like tomatoes, watermelon and papaya, may lower the risk of renal cell carcinoma...
Novartis has completed a series of transactions with GlaxoSmithKline (GSK), including the acquisition of certain oncology products and pipeline compounds from GSK, the creation of a world-leading consumer healthcare business through a joint venture...
Starting with this issue, Clinical Advances in Hematology & Oncology is launching a bimonthly column on kidney cancer in conjunction with the Kidney Cancer Association. The column will include information about the state of research, advances in treatment, and other news for oncologists who treat patients with kidney cancer. We will begin with an overview of the Kidney Cancer Association and its mission.
Since its founding in 1990 by the late Eugene P. Schonfeld, Ph.D., KCA has developed scores of highly effective relationships with organizations and institutions around the world.
Daniel J. George, MD, of Duke Cancer Institute, gives an overview of what is on the horizon in renal cell cancer (RCC) research. Topics discussed include emerging clinical trials, how to move forward with predictive biomarkers, clinical outcomes for RCC trials, and unmet needs in advanced RCC that Dr. George describes as being “imminently attainable.”
Standard single-agent treatment options offer meager prospects for metastatic sarcomatoid renal cell carcinoma (RCC) and poor-risk RCC, both of which demonstrate aggressive tumor biology and rapid clinical disease progression. However, results of a single-arm, open-label, phase II trial suggest that combining select treatment options may deliver the necessary punch to keep these aggressive forms of RCC in check (Abstract 408).
Interfering with two different stages of angiogenesis concurrently proves promising in clear cell renal cell carcinoma (RCC) based on early clinical results from the DART trial. In this phase Ib study of combined treatment with axitinib and dalantercept, objective responses have been observed in 25% of patients, along with a preliminary median progression-free survival duration of 8.3 months (Abstract 407).
|Powered by NeonCRM|